It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin , for accelerated approval, the company announced Aug. 27. Roche has already faced two significant pipeline setbacks this summer, a disappointing advisory committee review for Avastin (bevacizumab) in breast cancer and safety...